Unicycive Therapeutics Files 8-K with Corporate Updates
Ticker: UNCY · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Unicycive Therapeutics filed an 8-K on 6/17/25, updating corporate docs & security holder rights. Big changes afoot.
AI Summary
On June 17, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced material modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. Additionally, the filing included other events and financial statements and exhibits, indicating significant corporate actions and disclosures.
Why It Matters
This filing signals significant changes in Unicycive Therapeutics' corporate structure and security holder rights, which could impact investors and the company's strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates material modifications to security holder rights and amendments to corporate documents, which can introduce uncertainty and potential risks for investors.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 4300 El Camino Real, Suite 210 (address) — Principal executive offices
- Los Altos, CA 94022 (address) — Principal executive offices
FAQ
What specific material modifications were made to the rights of Unicycive Therapeutics' security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not elaborated upon in the provided text.
What amendments were made to Unicycive Therapeutics' articles of incorporation or bylaws?
The filing states that there were amendments to the articles of incorporation or bylaws, but the exact nature of these amendments is not detailed in the provided text.
What other events are reported in this 8-K filing?
The filing mentions 'Other Events' as a category, but the specific details of these events are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 17, 2025.
What is the principal executive office address for Unicycive Therapeutics, Inc.?
The principal executive office address for Unicycive Therapeutics, Inc. is 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Unicycive Therapeutics, Inc. (UNCY).